Fourth, although this study is limited to IMD from NSCLC, EGFR alterations are present in other cancers, including head and neck squamous cell carcinomas, anal squamous cell carcinomas, and gliomas.57,58 Future trials may support a role for osimertinib in IMD (or primary disease in the case of glioma) from these diseases, and future meta-analysis may examine the role of osimertinib in IMD from a larger patient population stratified by primary disease type. Here, EGFR is linked to central nervous system cancer.